{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-111027","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.474464+00:00","generated_at":"2026-05-30T10:41:45.714692+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months","bullets":["APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.","Near-complete pSTAT6 inhibition and sustained TARC suppression observed up to 9 months after a single dose.","No serious adverse events; treatment-emergent AEs were mild-to-moderate and unrelated to study drug.","Phase 2 proof-of-concept data in moderate-to-severe AD expected in 2H 2025.","Company plans R&D Day on December 2, 2024 to update on APG777 and pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-111027","json":"https://secwatch.observer/filing/0001104659-24-111027.json","markdown":"https://secwatch.observer/filing/0001104659-24-111027.md","text":"https://secwatch.observer/filing/0001104659-24-111027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924111027/0001104659-24-111027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924111027/tm2426705d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:41:45.714692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}